Saranac Partners Ltd Buys Shares of 8,299 Abbott Laboratories $ABT

Saranac Partners Ltd bought a new position in Abbott Laboratories (NYSE:ABT) in the 2nd quarter, HoldingsChannel reports. The fund bought 8,299 shares of the healthcare product maker’s stock, valued at approximately $753,000.

Other hedge funds also recently made changes to their positions in the company. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories in the 4th quarter worth approximately $25,000. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories in the 4th quarter valued at approximately $25,000. Purpose Unlimited Inc. bought a new stake in Abbott Laboratories during the 4th quarter valued at $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in Abbott Laboratories during the 4th quarter worth $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories in the fourth quarter worth $26,000. Institutional investors own 75.18% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New infant formula expands Abbott’s nutrition portfolio. Abbott launched Similac 360 Total Care Made With Whole Milk, described as the first commercially sterile, ready-to-feed liquid whole-milk infant formula available in the U.S. The product targets growing parental interest in whole-milk formulas while offering convenience at a price similar to Similac’s powdered formula. Wider distribution and consumer adoption could provide incremental growth for Abbott’s Nutrition segment. Abbott launches whole-milk liquid infant formula
• Positive Sentiment: Analysts remain optimistic despite relative underperformance. Coverage notes that ABT has lagged the broader healthcare sector over the past year, but Wall Street analysts continue to express confidence in the company’s outlook. Recent earnings also showed revenue growth, an earnings-per-share beat and reaffirmed 2026 guidance, supporting the bullish view. Abbott stock and healthcare-sector performance
• Neutral Sentiment: Abbott is positioning the launch around changing consumer and policy preferences. The whole-milk formula introduction aligns with interest in “Make America Healthy Again” themes, but the financial impact will depend on demand, pricing and market share gains. Abbott and the Make America Healthy Again movement
• Negative Sentiment: Formula-related advertising scrutiny remains a risk. In a challenge brought by Abbott, the National Advertising Division supported certain Kendamil whole-milk claims but recommended that other nutritional, ingredient and heritage claims be modified or discontinued. The decision is not a direct finding against Abbott, but it highlights competitive scrutiny in the infant-formula market. NAD decision on Kendamil infant formula claims

Analysts Set New Price Targets

A number of research analysts have recently commented on ABT shares. The Goldman Sachs Group lowered their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. BTIG Research increased their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Wells Fargo & Company boosted their price target on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Stock Performance

Shares of ABT opened at $108.86 on Wednesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm’s 50 day moving average is $103.43 and its 200-day moving average is $100.09. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The stock has a market capitalization of $188.37 billion, a P/E ratio of 35.23, a P/E/G ratio of 2.05 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.